Abstract
Thirteen patients (12 previously treated, 1 previously untreated) with squamous cell carcinoma of the head and neck were each given 1.0g or 1.5g of FT-207 suppositories a day. Ten of the 13 patients, who were treated as such for at least 28 days, were evaluated for clinical effects. Side effects for any of the patients were studied. An overall response rate of 40% was obtained. There was 1 complete response, 3 partial responses, 1 no change, and 5 progressive diseases. Fifty per cent regression of tumor size among all the patients was seen after an average administration of 30.6g. Side effects were observed in 69.2% of all the cases. Three patients discontinued the administration, due to appetite loss, nausea and vomiting, diarrhea, and stomatitis. FT-207 suppositories appear effective in treating head and neck carcinoma patients who have previously been treated with other anticancerants or radiation.
